Studying Malnutrition And Sarcopenia In Older Adults With Acute Myeloid Leukemia

Acute Myeloid Leukemia Clinical Trial

Official title:

Investigating The Prognostic Significance Of Malnutrition And Sarcopenia In Older Adults With Acute Myeloid Leukemia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05458258
• Other study ID #: IRB22-0397
• Status: Recruiting
• Start date: March 1, 2023
• Est. completion date: December 1, 2027

Study information

• Verified date: June 2024
• Source: University of Chicago
• Contact: Wendy Stock, MD
• Phone: 773-834-8982
• Email: wstock[@]medicine.bsd.uchicago.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study will explore how malnutrition (poor nutrition/diet) and sarcopenia (a condition that causes a loss of muscle and bone mass) affects study participants over the age of 60 with acute myeloid leukemia (AML) who will receive induction chemotherapy (chemotherapy given as the first treatment to help cancer go into remission) and/or cancer drugs as part of standard care for AML. By studying how these nutritional and skeletal factors, doctors leading this study hope to learn how malnutrition and sarcopenia may be able to predict certain outcomes --such as how long study participants with poor nutrition and muscle loss can live after chemotherapy- for older (age 60+) individuals with AML.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 82
• Est. completion date: December 1, 2027
• Est. primary completion date: December 1, 2027
• Gender: All
• Age group: 60 Years and older

Eligibility

Inclusion Criteria:

• Older Adult patients (greater than or equal to 60 years of age)
• New diagnosis of acute myeloid leukemia (AML)
• Receiving induction therapy (intensive or low intensity therapy)
• Willing and able to provide written informed consent

Exclusion Criteria:

• Presence of a pacemaker or defibrillator.
• Participants who are pregnant at the time of enrollment.
• Anyone unable/unwilling to follow protocol requirements

Related Conditions & MeSH terms

• Acute Myeloid Leukemia
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Malnutrition
• Sarcopenia

Intervention

Device:
• Bioelectrical Impedence Analysis Device
A device that helps measure body composition, in particular body fat and muscle mass based on based on the rate at which an electrical current travels through the body.

Other:
• 6 Minute Walk Test
Defined as the distance the participant is able to walk in 6 minutes. Participants will be instructed to perform laps from the 0- to 30 minutes mark and back again for a total of 6 min in an outpatient or inpatient setting on a flat, pre-defined course. Participants will be instructed that goal of the test is to walk as far as possible.

Diagnostic Test:
• Computed Tomography Scans to Measure Skeletal Muscular Index
Computed tomography scans (a type of x-ray) that will measure the skeletal muscular index (the ratio of the muscle in your arms and legs to your height).
• Blood Test/Blood Draw
Blood will be drawn through a need inserted into the participant's arm. This blood will be used to measure the participant's nutrition levels.

Other:
• Hand Grip Strength Test
Grip strength in both hands will be measured using an adjustable hydraulic grip strength dynamometer (a device that is gripped to measure hand strength). The best performance of three trials will be selected for each hand, with averages of the left and right hand used in analyses.

Locations

Country	Name	City	State
United States	University of Chicago Medicine Comprehensive Cancer Center	Chicago	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
University of Chicago

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Treatment-Related Mortality Rates Based on Incidence of Sarcopenia in All Study Participants	This study's primary endpoint aims to measure the association of sarcopenia in study participants with their treatment-related mortality rate (how long the participant can stay alive 60 days after study treatment/registration). The incidence of sarcopenia in study participants will be measured using computed tomography-defined skeletal muscular index , hand grip strength test, and a 6-minute walk test. Treatment related mortality will be defined as the percent of patients no longer alive at 60 days after study registration.	60 days
Secondary	The prognostic impact of malnutrition and sarcopenia on treatment-related mortality rates and overall survival in study participants with AML	After pre-induction assessment (including assessments for sarcopenia and malnutrition), subjects will be prospectively followed for treatment-related mortality and overall survival assessments. Overall survival will be measured from date participants start on study to either death or last follow-up in accordance with 2017 European Leukemia Net recommendations. Treatment-related mortality rates will be defined as the percent of patients no longer alive at 60 days after registration.	60 days
Secondary	Incidence of Malnutrition Among Participants in Group 1 Compared to Incidence of Malnutrition in Healthy Control Group	The incidence of malnutrition in older adults (=60 years) with newly diagnosed AML undergoing intensive induction chemotherapy compared to the incidence of malnutrition in participants in the healthy control group. Incidence of malnutrition in both groups will be as assessed by participant questionnaires (known as subjective global assessments), blood tests , and Standardized bioelectrical impedance (BI) phase angle ( a measurement of the participant's body mass using a medical device).	60 days
Secondary	Incidence of Sarcopenia Among Participants in Group 1 Compared to Incidence of Sarcopenia in Healthy Control Group	Incidence of sarcopenia in both study groups will be assessed by will be assessed by using computed tomography-defined skeletal mass index at L1, hand grip strength, and a 6-minute walk test.	60 days